UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Glioblastoma Multiforme, AdultGlioblastoma, IDH-mutant
Interventions
RADIATION

Dose escalation + Reduced Margin Adaptive Radiotherapy

Concurrent chemoradiation with temozolomide (TMZ) over 3 weeks (40 Gy in 15 fractions). The gross tumor volume (GTV) plus margin will be boosted simultaneously (SIB) to 52.5 Gy in 15 fractions. Radiation will be delivered on the MR-Linac with a reduced clinical target volume (CTV) margin of minimum 5 mm and a weekly online adaptive approach.

Trial Locations (1)

M4N 3M5

RECRUITING

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER